Table 1.
Patients’ characteristics.
| N = 20 | |
|---|---|
| Gender (M/F) | 11/9 |
| Age (years, mean ± SD) | 52 ± 14 |
| History of rejection in the year preceding vaccination, n | 0 |
| Time between vaccine and transplantation (months, IQR 1; 3) | 56 (22; 112) |
| No induction therapy, n (%) | 8 (40) |
| Induction therapy, n (%) | 12 (60) |
| Anti-IL2 receptor blockers | 5 (42) |
| Polyclonal antibodies | 7 (58) |
| Type of immunosuppressive regimen *, n (%) | |
| Calcineurin-inhibitors | 17 (85) |
| Tacrolimus | 16 (80) |
| Ciclosporin A | 1 (5) |
| Mycophenolic acid | 13 (65) |
| mTOR inhibitors | 7 (35) |
| Steroids | 18 (90) |
| Belatacept | 3 (15) |
| Neutrophil count before vaccination (/mm3, mean ± SD) | 5622 ± 2842 |
| Lymphocyte count before vaccination (/mm3, mean ± SD) | 1571 ± 764 |
| CD4+ T-cell count before vaccination (/mm3, mean ± SD) | 546 ± 311 |
| CD8+ T-cell count before vaccination (/mm3, mean ± SD) | 451 ± 308 |
| CD19+ T-cell count before vaccination (/mm3, mean ± SD) | 91 ± 85 |
| NK cell count before vaccination (/mm3, mean ± SD) | 253 ± 232 |
| eGFR before vaccination (mL/min/1.73 m2) | 51 ± 19 |
| Neutrophil count before 4th dose (/mm3, mean ± SD) | 6125 ± 2978 |
| Lymphocyte count before 4th dose (/mm3, mean ± SD) | 1061 ± 805 |
| eGFR before 4th dose (mL/min/1.73 m2) | 46 ± 23 |
* Target tacrolimus C0: 5–7 ng/mL, target ciclosporin A C2: 500–1000 ng/mL, everolimus C0: 3–8 ng/mL. Mycophenolic acid was taken at 360 mg b.i.d, prednisone at 5 mg/d, and belatacept at 5 mg/kg monthly.